Mutant fibroblast growth factor receptor 3 induces intracellular signaling and cellular transformation in a cell type- and mutation-specific manner.
about
Small molecule FGF receptor inhibitors block FGFR-dependent urothelial carcinoma growth in vitro and in vivo.Genetic and Epigenetic Alterations in Bladder CancerA place for precision medicine in bladder cancer: targeting the FGFRs.Phosphatidylinositol 3-kinase (PI3K) pathway activation in bladder cancerFGFR3, HRAS, KRAS, NRAS and PIK3CA mutations in bladder cancer and their potential as biomarkers for surveillance and therapy.Somatic mutation of fibroblast growth factor receptor-3 (FGFR3) defines a distinct morphological subtype of high-grade urothelial carcinoma.FGFR1-induced epithelial to mesenchymal transition through MAPK/PLCγ/COX-2-mediated mechanisms.Nonamplified FGFR1 is a growth driver in malignant pleural mesotheliomaFibroblast growth factor receptors-1 and -3 play distinct roles in the regulation of bladder cancer growth and metastasis: implications for therapeutic targeting.Mosaic RASopathies.FGFR3-TACC3 fusion proteins act as naturally occurring drivers of tumor resistance by functionally substituting for EGFR/ERK signaling.Targeting mutant fibroblast growth factor receptors in cancer.FGF receptor inhibitors: role in cancer therapy.Molecular biology of bladder cancer: new insights into pathogenesis and clinical diversity.ASP5878, a selective FGFR inhibitor, to treat FGFR3-dependent urothelial cancer with or without chemoresistance.Spectrum of genomic alterations in FGFR3: current appraisal of the potential role of FGFR3 in advanced urothelial carcinoma.Genetic Alterations in the Molecular Subtypes of Bladder Cancer: Illustration in the Cancer Genome Atlas Dataset.An integrated genomic, transcriptional and protein investigation of FGFRL1 as a putative 4p16.3 deletion target in bladder cancer.Parallel RNA interference screens identify EGFR activation as an escape mechanism in FGFR3-mutant cancer.Oncogenic FGFR3 gene fusions in bladder cancer.Mechanisms of FGFR3 actions in endocrine resistant breast cancer.A Decade of FGF Receptor Research in Bladder Cancer: Past, Present, and Future Challenges.Landscape of activating cancer mutations in FGFR kinases and their differential responses to inhibitors in clinical use.PIK3CA mutation spectrum in urothelial carcinoma reflects cell context-dependent signaling and phenotypic outputs.PIK3CA gene alterations in bladder cancer are frequent and associate with reduced recurrence in non-muscle invasive tumors.Comparative Aspects of BRAF Mutations in Canine Cancers.Signaling by FGFR3 in diseaseSignaling by FGFR3 point mutants in cancerPI3K/AKT pathway activation in bladder carcinogenesis.Unique signalling connectivity of FGFR3-TACC3 oncoprotein revealed by quantitative phosphoproteomics and differential network analysis.Activated FGFR1 mutants and fusions bind PLCG1Activated FGFR2 mutants bind PLCG1Activated FGFR3 mutants bind PLCG1Activated FGFR4 mutants bind PLCG1Stat6 cooperates with Sp1 in controlling breast cancer cell proliferation by modulating the expression of p21(Cip1/WAF1) and p27 (Kip1).Bladder cancer.A comprehensive immunohistochemical and molecular approach to the PI3K/AKT/mTOR (phosphoinositide 3-kinase/v-akt murine thymoma viral oncogene/mammalian target of rapamycin) pathway in bladder urothelial carcinoma.
P2860
Q27851612-4ED9EE76-305F-4302-B836-8EE00FFDAF1CQ28074732-B63D7729-FE38-41A1-855E-65819E6A7D97Q30249143-ED523718-B877-401A-B890-2F0135270F2DQ33554443-FAB2E06D-EAAC-4096-B1E4-8F40C47B18F2Q33745140-39C6A1B0-5EAE-445D-AA1B-D5357056D8EEQ33891125-88DAE361-34CA-4BEF-B2D5-0E8791EA2B0CQ34305855-F045D45F-45F8-4546-8B81-08B0FB008F36Q34364821-C0AA3625-5ECB-4EBE-BE36-63F95043C5E0Q34611953-B2CDFCEC-4B77-4866-886D-5ACE42D01696Q36604645-6F3D8679-BEA4-44F8-B87B-525DE6066E09Q37622191-74D821F7-8AA2-4192-981E-546BB4B8C6F5Q37849013-2AB4D772-451E-46B1-8F08-E936895336E9Q37981986-CAB21705-9D29-4762-B823-CCB502963A63Q38297729-4F5EAFB1-055D-4985-9543-C58D78A1A619Q38729065-3E1A22EE-78AE-4C5B-9D20-7EEE5E603BA6Q38810603-3D3869DD-E67F-4E4B-94A5-99BC270E8B53Q38862963-E9E86F3E-4E3F-4886-A57B-D2D14DDEFAFAQ39138319-2FE3B18D-845F-45A3-BF37-EAD7F3646245Q39142753-C307CD79-1F26-4A77-BBC5-8FC47409653AQ39240290-014A6ABF-E1D0-469D-9BB9-D99C3CA30E5BQ39500283-CA2C0353-DF7F-4C99-8144-03721E2A1134Q39568069-3598D638-984C-49B9-8465-4064E703FD49Q39908219-33B62943-952D-4529-8C38-6AC4BC784D7AQ42798110-080B1EA3-1FB6-481C-8F3B-6CBD80C949EEQ44581657-3E2C7BC5-512A-4771-90F3-0CEAC55B877CQ44876415-723D5C8A-5004-4660-B5CA-39F48D091CF6Q45314373-47D97F12-B636-4681-9C88-B91E4AD176C3Q45314374-AA2DD509-9B07-4FAA-A3D1-FE689B5753CFQ46976450-751B3D9D-524D-4B70-94D1-43386043347DQ47149560-5C614B62-1B90-491A-8332-07C3C82727F7Q50288695-B817C3A2-5D0F-4621-AC56-5DF5160E335DQ50288729-9CB9DD8E-FF5A-412E-A740-2BAC493A0056Q50288752-70C2B5AD-3A47-4503-AAA0-857657F9E94BQ50288786-8454F6D7-A944-449E-B40B-0EF134DF415CQ51755890-E7E9FC47-F331-4F1F-9207-1034378B17B7Q52810295-D86156BB-57BE-4840-8DC8-E8E39C6508AFQ54285690-94AA9900-BE4B-4D6F-975F-E76754129468
P2860
Mutant fibroblast growth factor receptor 3 induces intracellular signaling and cellular transformation in a cell type- and mutation-specific manner.
description
2009 nî lūn-bûn
@nan
2009年の論文
@ja
2009年論文
@yue
2009年論文
@zh-hant
2009年論文
@zh-hk
2009年論文
@zh-mo
2009年論文
@zh-tw
2009年论文
@wuu
2009年论文
@zh
2009年论文
@zh-cn
name
Mutant fibroblast growth facto ...... and mutation-specific manner.
@en
Mutant fibroblast growth facto ...... and mutation-specific manner.
@nl
type
label
Mutant fibroblast growth facto ...... and mutation-specific manner.
@en
Mutant fibroblast growth facto ...... and mutation-specific manner.
@nl
prefLabel
Mutant fibroblast growth facto ...... and mutation-specific manner.
@en
Mutant fibroblast growth facto ...... and mutation-specific manner.
@nl
P2093
P2860
P356
P1433
P1476
Mutant fibroblast growth facto ...... and mutation-specific manner.
@en
P2093
C G L'Hôte
D C Tomlinson
E di Martino
M A Knowles
P2860
P2888
P304
P356
10.1038/ONC.2009.280
P407
P577
2009-09-14T00:00:00Z